Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment

Molecular Psychiatry

Volumn 5, Issue 2, 2000, Pages 150-158

  Arolt, V ^a   Rothermundt, M ^b   Wandinger, K P ^b   Kirchner, H ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b NONE

Author keywords

Cytokines; Immunology; Interferon gamma; Interleukin 2; Schizophrenia

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; MALE; ONSET AGE; PRIORITY JOURNAL; SCHIZOPHRENIA; T LYMPHOCYTE;

EID: 0034057150     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000650     Document Type: Article

References (80)

1. 1 Lehmann-Facius H. Liquoruntersuchungen bei destruktiven Erkrankungen des Nervensystems, besonders bei Schizophrenien. Neurol Psychiatrie 1937; 157: 109-115.
2. 2 Ganguli R, Brar JS, Chengappa KNR, Yang ZW, Nimgaonkar VL, Rabin BS. Autoimmunity in schizophrenia. Ann Med 1993; 25: 489-496.
3. 3 Kroomer G, Martinez C. Cytokines and autoimmune disease. Clin Immunol Immunopathol 1991; 61: 275-295.
4. 4 Ruschen S, Stellberg W, Warnatz H. Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid patients are different from those of healthy controls. Clin Exp Immunol 1992; 89: 32-37.
5. 5 Sanders ME, Makoba MW, Sharrow SO, Stephany D, Springer TA, Young HA et al. Human memory T-lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2 and LFA-1) and three other molecules (UCHL-1, Cdw29 and Pgp-1) and have enhanced interferon-gamma production. J Immunol 1988; 140: 1401-1407.
6. 6 Bruce LC, Peebles AMS. Clinical and experimental observations on catatonia. J Ment Sci 1903; 49: 614-628.
7. 7 Kirch DG. Infection and antoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr Bull 1993; 19: 355-370.
8. 8 Villemain F, Chatenoud L, Guillibert E, Pelicier Y, Bach JF. Decreased production of interleukin-2 in schizophrenia. Ann NY Acad Sci 1987; 469: 669-675.
9. 9 Kolyaskina GI, Morozov TP, Sekirina TP, Burbayeya GS. Immunological and Virological Studies in Schizophrenia. Presented at the Second World Congress on Viruses, Immunity, and Mental Health, October 6, 1988, Quebec.
10. 10 Villemain F, Chatenoud L, Calinowski A, Homo-Delarche F, Ginestet D, Loo H et al. Aberrant T-cell mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 1989; 146: 609-616.
11. 11 Ganguli R, Rabin BS, Belle SH. Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 1989; 26: 427-430.
12. 12 Sirota P, Fishman P, Elizur A, Djaldetty M. Lymphokine production in schizophrenic patients. Biol Psychiatry 1990; 27: 173A.
13. 13 Bessler H, Levental Z, Karp L. Modai I, Djaldetti M, Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 1995; 38: 297-302.
14. 14 Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H. Lymphokine production in leukocyte cultures of patients with schizophrenia. Schizophr Res 1995; 15: 237-242.
15. 15 Wilke I, Arolt V, Hornberg M, Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenics. Eur Arch Psychiatry Clin Neurosci 1996; 246: 279-284.
16. 16 Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in nouroleptic-free schizophrenic patients. Am J Psychiatry 1993; 150: 1408-1410.
17. 17 McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995; 152: 1291-1297.
18. 18 Ganguli R, Rabin BS. Increased serum interleukin-2 receptor in schizophrenic and brain damaged subjects. Arch Gen Psychiatry 1989; 46: 292.
19. 19 Rapaport MH, McAllister CG, Pickar D, Nelson DL, Paul SM, Elevated levels of soluble interleukin-2 receptors in schizophrenia. Arch Gen Psychiatry 1989; 46: 291-292.
20. 20 Preble OT, Torrey EF. Serum interferon in patients with psychosis. Am J Psychiatry 1985; 142: 1184-1186.
21. 21 Schindler L, Leroux M, Beck J, Moises HW, Kirchner H. Studies of cellular immunity, serum interferon titers, and natural killer cell activity in schizophrenic patients. Acta Psychiatr Scand 1986; 73: 651-657.
22. 22 Becker D, Kritschmann E, Floru S, Shlomo-David Y, Gotlieb-Stematsky T. Serum interferon in first psychotic attack. Br J Psychiatry 1990; 157: 136-138.
23. 23 Gattaz WF, Dalgalanondo P, Schröder HC. Abnormalities in serum concentrations of interleukin-2 and interferon-γ in schizophrenia not detected. Schiz Res 1992; 6: 237-241.
24. 24 Ahokas A, Rimon R, Koskemieni M, Vaheri A, Julkunen I, Sarna S. Viral antibodies and interferon in acute psychiatric disorders. J Clin Psychiatry 1987; 48: 194-196.
25. 25 Katila H, Cantell K, Hirvonen S, Rimon R. Production of interferon alpha and gamma by lymphocytes from patients with schizophrenia. Schizophr Res 1989; 2: 361-365.
26. 26 Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M et al. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 947-957.
27. 27 Moises HW, Schindler L, Leroux M, Kirchner H. Decreased production of interferon-gamma in leucocyte cultures of schizophrenic patients. Acta Psychiat Scand 1985; 72: 45-50.
28. 28 Kirchner H, Kleinicke C, Diegel W. A whole blood technique for testing production of human Interferon by leukocytes. Immunol Meth 1982; 48: 213-219.
29. 29 Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H. Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry 1996; 40: 1294-1297.
30. 30 Arolt V, Weitzsch C, Wilke I, Nolte A, Pinnow M, Kirchner H. Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Res 1997; 66: 145-151.
31. 31 Arolt V, Weitzsch C. Rothermundt M, Eckhoff D, Kirchner H. Interferon-gamma in schizophrenia. Adv Biol Psychiatry 1997; 18: 57-66.
32. 32 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812.
33. 33 Kay SR, Fishbein A, Oppler LA. The Positive and Negative Syndrom Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
34. 34 Zier KS, Leo MM, Spielman RS, Baker L. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes 1984; 33: 552-555.
35. 35 Roncarolo MG, Zoppo M, Bacchetta R, Gabbiano C, Sacchetti C, Cerutti F et al. Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes. Clin Immunol Immunopathol 1988; 49: 53-62.
36. 36 Kaye WA, Adri MN, Soeldner JS, Rabinowe SL, Kaldany A, Kahn CR et al. Aquired defect of interleukin-2 production in patients with type I diabetes mellitus. N Engl J Med 1986; 315: 920-924.
37. 37 Catheley GB, Amor B, Fournier C. Defective IL-2 production in active rheumatoid arthritis: regulation by radiosensitive suppressor cells. Clin Rheumatol 1986; 5: 482-492.
38. 38 Jokinen EI, Mottonen TT, Hannonen PJ, Arvilommi HS. Association of in vitro immune functions with the severity of the disease in rheumatoid arthritis. Br J Rheumatol 1993; 32: 550-555.
39. 39 Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995; 22: 406-412.
40. 40 Cuadrado MJ, Marubayashi M, Ortega C, Fernandez-Arcas N, Garcia-Cozar F, Pena J et al. Relationship of IL-2, IL-2R (CD25+), soluble IL-2R, and 1L-4 with disease activity in SLE patients. Lupus 1993; 2: 257-260.
41. 41 Kucharz EJ, Sierakowski SJ, Goodwin JS. Lithium in vitro enhances interleukin-2 production by T cells from patients with systemic lupus erythematosus. Immunopharmacol Immunotoxicol 1993; 15: 515-523.
42. 42 Samosonov MY, Tilz GP, Egorova O, Reibnegger G, Balabanova RM, Nassonov EL et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995; 4: 29-32.
43. 43 Suzuki T, Suzuki N, Engleman EG, Mitsushima Y, Sakane T. Low serum levels of dehydroepiandrostorone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 1995; 99: 251-255.
44. 44 Corrales JJ, Orfao A, Lopez A, Mories MT, Miralles JM, Ciudad J. Analysis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves' disease. Relationship with disease activity. Cytometr 1997; 30: 118-123.
45. 45 Eisenstein Z, Engelsman E, Weiss M, Kalechman Y, Sredni B. Modulation of the IL-2 production defect in vitro in Graves' disease. Exp Immunol 1994; 96: 323-328.
46. 46 Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996; 45: 322-333.
47. 47 Sehmaj K, Nowak Z, Tchorzewski H. Interloukin-1 and interleukin-2 production by peripheral blood mononuclear cells in multiple sclerosis patients. J Neurol Sci 1988; 85: 67-76.
48. 48 Wandinger KP, Wessel K, Neustock P, Siekhaus A, Kirchner H. Diminished production of type I Interferon and interleukin-2 in patients with multiple sclerosis. J Neurol Sci 1997; 149: 87-93.
49. 49 Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV. Senim interleukin-2 concentrations in Guillain-Barré syndrome and chronic ideopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991; 30: 48-53.
50. 50 Zoukos Y, Kidd D, Woodroofe MN, Kendall BE, Thompsom AJ, Cuzner ML. Increased expression of high affinity IL-2 receptors and beta-adrenoreceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. Brain 1994; 117: 307-315.
51. 51 Ciampolillo A, Guastamachia E, Caragiulo L, Lollino G, DeRobertis O, Lattanzi V et al. In vitro secretion of interleukin-1 beta and interferon-gamma by peripheral blood lymphomononuclear cells in diabetic patients. Diabetes Res Clin Prac 1993; 21: 87-93.
52. 52 Vonherrath MG, Oldstone MBA. Interferon gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med 1997; 185: 531-539.
53. 53 Baldeon ME, Neece DJ, Nandi D, Monaco JJ. Gaskins HR. Interferon gamma independently activates the MHC class I antigen processing pathway and diminishes glucose responsiveness in pancreatic cell lines. Diabetes 1997; 46: 770-778.
54. 54 Zangerle PF, DeGroote D, Lopez M, Meuleman RJ. Vrindts Y, Fauchet F et al. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma, and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis. Cytokine 1992; 4: 568-575.
55. 55 Gattorno M, Facchetti P, Ghiotto F, Vignola S, Buoncompagni A, Prigione I et al. Synovial fluid T cell clones from oligoarthricular juvenile arthritis patients display a prevalent TH1/TH0-type pattern of cytokine secretion irrespective of immunophenotype. Clin Exp Immunol 1997; 109: 4-11.
56. 56 Dolhain RJEM, Vanderheiden AN, Torhaar NT, Breedveld FC, Miltenburg AMM. Shift towards T-lymphocytes with a T-helper1 cytokine secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheumatism 1996; 39: 1961-1969.
57. 57 Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 1995; 45 (suppl 6): 11-15.
58. 58 Beck J, Rondot P, Catinot L, Falcoff L, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78: 318-323.
59. 59 Merrill J, Jonakait GM. Interactions of the nervous and immune systems in development, normal brain homeostasis, and disease. FASEB J 1995; 9: 611-618.
60. 60 Jonakait GM. Interferon-gamma promotes cholinergic differentiation of embrionic septal nuclei and adjacent basal forebrain. Neuron 1995; 12: 1149-1159.
61. 61 Nistico G, DeSarro G. Is interleukin-2 a neuromodulator in the brain? Trend Neurosci 1991; 14: 146-150.
62. 62 Alonso R, Chaudieu I, Diorio J, Krishnamurthy A, Quirion R, Boksa P. Interleukin-2 modulates evoked release of 3H-dopamine in rat cultured mesencephalic cells. J Neurochem 1993; 61: 1284-1290.
63. 63 Lapchak PA. A role for interleukin-2 in the regulation of striatal dopaminergic function. Neuro Report 1992; 3: 165-168.
64. 64 Pasternak KI, Timo-Iara G, Rodrigues CJ, Maria DA, Duarte AJS, Paiva L et al. Circumscribed lesion of the medial forebrain bundle area causes structural impairment of lymphoid organs and severe depression of immune function in rats. Mol Psychiatry 1998; 3: 397-404.
65. 65 Claret E, Renversez J-C, Zheng X, Bonnefoix T, Sotto J-J. Valid estimation of IL-2 secretion by PHA-stimulated T-cell clones absolutely requires the use of anti-CD25 monoclonal antibody to prevent IL-2 consumption. Immunol Lett 1992; 33: 179-186.
66. 66 Rapaport MH, Torrey EF, McAllister CG, Nelson DL, Pickar D, Paul SM. Increased serum interleukin-2 receptors in schizophrenic monozygotic twins. Eur Arch Psychiatr Clin Neurosci 1993; 242: 7-10.
67. 67 Ganguli R, Brar JS, Ghengappa KNR, DeLeo M, Yang ZW, Shurin G et al. Mitogen-stimulated interleukiu-2 production in never-medicated, first episode schizophrenic patients. Arch Gen Psychiatry 1995; 52: 668-671.
68. 68 Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology 1938; 37: 186-193.
69. 69 McAllister CG. Rapaport MH, Pickar D, Paul SM. Effects of short-term administration of antipsychotic drugs on lymphocite subsets in schizophrenic patients. Arch Gen Psychiatry 1989; 46: 956-957.
70. 70 Müller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein K. Cellular immunity in schizophrenic patients before and during nenroleptic treatment. Psychiatr Res 1991; 37: 147-160.
71. 71 Rapaport MH, Lohr JB. Serum soluble interleukin-2 receptors in nenroleptic naive schizophrenic subjects and in medicated subjects with and without tardive dyskinesia. Psychiatr Scand 1994; 90: 311-315.
72. 72 Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997; 37: 75-86.
73. 73 Hinzo-Selch D, Becker EW, Stein GM, Berg PA, Mullington J. Holsboer F et al. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology 1998; 19: 114-122.
74. 74 Pollmächer T, Hinze-Selch D, Mullington J, Holsboer F. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors (letter). Arch Gen Psychiatry 1995; 52: 877.
75. 75 Ganguli R, Brar JS, Rabin BS. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors (comment). Arch Gen Psychiatry 1995; 52: 878.
76. 76 Sasaki T, Nanko S, Fukuda R, Kawate T, Kunugi H, Kazamatsuri H. Changes of immunological functions after acute exacerbation in schizophrenia. Biol Psychiatry 1994; 35: 173-178.
77. 77 Gudewill S, Pollmacher T, Vedder H, Schreiber W, Fassbender K, Holsboer F. Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry Clin Neurosci 1992; 242: 53-56.
78. 78 Uthgenannt D, Schoolmann D, Pietrowsky R, Fehm HL, Born J. Effects of sleep on the production of cytokines in humans. Psychosom Med 1995; 57: 97-104.
79. 79 Irwin M, Thompson J, Miller C, Gillin JG, Ziegler M. Effects of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans: clinical implications. J Clin Endocrinol Metab 1999; 84: 1979-1985.
80. 80 Appelborg B, Katila H, Rimon R. Plasma interleukin-1 beta and sleep architecture in schizophrenia and other nonaffective psychoses. Psychosom Med 1997; 59: 529-532.